This article is authored by Saransh Chaudhary, president, Global Critical Care, Venus Remedies Ltd and CEO, Venus Medicine ...

Hedge funds revealed their top investment ideas, ranging from Chinese self-driving taxis, an Indian drug retailer, to a ...

Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

Onesource Specialty, a newly demerged pharma CDMO, is set to benefit from the $150 billion GLP-1 weight-loss drug boom with ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

AI is reshaping labs and Clever Culture’s tech is gaining Big Pharma attention as diagnostics and cleanrooms go digital. Step ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

The administration of US President Donald Trump has taken a series of actions since January, 2025 that directly threaten the ...

Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 ...

India’s offer comes in the backdrop of the US administration’s stated desire to sharply reduce local drug prices, and gains ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs; The agreement includes pr ...